ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2016
Hepatitis E in blood donors: investigation of the natural course of asymptomatic infection, Germany, 2011.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 48 citations in OpenAlex.
- Article
- The crucial but insufficient role of E2s domain's residues 490 and 492 in determining the host tropism of hepatitis E virus.Nature communications · 2026Article
- Performance of Elecsys Anti-HEV IgG and IgM Assays for the Detection of Acute, Recent or Past Hepatitis E Virus Infection.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Hepatitis E virus: from innate sensing to adaptive immune responses.Nature reviews. Gastroenterology & hepatology · 2024Review
- Kinetics of Hepatitis E Virus Infections in Asymptomatic Persons.Emerging infectious diseases · 2024Article
- Calibrating Hepatitis E Virus Serological Assays Using Asymptomatic Specimens Obtained in Japan.Microbiology spectrum · 2022Article
- Article
- Review
- Hepatitis E virus as a trigger for Guillain-Barré syndrome.BMC neurology · 2021Article
- Anti-HEV IgG Avidity Testing: Utility for Diagnosing Acute and Resolved Genotype 3 Infections.Viruses · 2021Article
- Clinical Characteristics of Acute Hepatitis E and Their Correlation with HEV Genotype 3 Subtypes in Italy.Pathogens (Basel, Switzerland) · 2020Article
- Prevalence and 9-year incidence of hepatitis E virus infection among North Italian blood donors: Estimated transfusion risk.Journal of viral hepatitis · 2020Article
- Comprehensive Evaluation of Hepatitis E Serology and Molecular Testing in a Large Cohort.Pathogens (Basel, Switzerland) · 2020Article
- Review
- Adaptive Immune Responses in Hepatitis A Virus and Hepatitis E Virus Infections.Cold Spring Harbor perspectives in medicine · 2019Review
- Transmission and Epidemiology of Hepatitis E Virus Genotype 3 and 4 Infections.Cold Spring Harbor perspectives in medicine · 2018Review
- Long-term HEV carriers without antibody seroconversion among eligible immunocompetent blood donors.Emerging microbes & infections · 2018Article
- Hepatitis E Virus Genotype 3 Genomes from RNA-Positive but Serologically Negative Plasma Donors Have CUG as the Start Codon for ORF3.Intervirology · 2018Article
- Transfusion-Transmitted Hepatitis E: NAT Screening of Blood Donations and Infectious Dose.Frontiers in medicine · 2018Article
- A cross-sectional study among Polish hunters: seroprevalence of hepatitis E and the analysis of factors contributing to HEV infections.Medical microbiology and immunology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asymptomatic hepatitis E virus (HEV) infections have been found in blood donors from various European countries, but the natural course is rarely specified. Here, we compared the progression of HEV viraemia, serostatus and liver-specific enzymes in 10 blood donors with clinically asymptomatic genotype 3 HEV infection, measuring HEV RNA concentrations, plasma concentrations of alanine/aspartate aminotransferase, glutamate dehydrogenase and bilirubin and anti-HEV IgA, IgM and IgG antibodies. RNA concentrations ranged from 77.2 to 2.19×10(5) IU/mL, with viraemia lasting from less than 10 to 52 days. Donors showed a typical progression of a recent HEV infection but differed in the first detection of anti-HEV IgA, IgM and IgG and seropositivity of the antibody classes. The diagnostic window between HEV RNA detection and first occurrence of anti-HEV antibodies ranged from eight to 48 days, depending on the serological assay used. The progression of laboratory parameters of asymptomatic HEV infection was largely comparable to the progression of symptomatic HEV infection, but only four of 10 donors showed elevated liver-specific parameters. Our results help elucidate the risk of transfusion-associated HEV infection and provide a basis for development of screening strategies. The diagnostic window illustrates that infectious blood donors can be efficiently identified only by RNA screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.